Clinical and pharmacokinetic evaluation of a sustained-release liquid theophylline preparation

Margaret Frank Guill, Albert W. Pruitt, Roy E. Altman, Terri E. Lawless, David A. Brown, Robert H. DuRant, Peter B. Bottini

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Theolan Suspension is the first long-acting liquid theophylline dosage form. A crossover study comparing the pharmacokinetic and clinical response to Theolan Suspension (administered every 12 hours) with aminophylline solution (administered every 8 hours) in children younger than 12 years of age is reported. Twenty-seven patients completed the study: 17 children were aged 6 years or younger and five patients were 3 years or younger. All patients were withdrawn from bronchodilator therapy and then were titrated to clinically effective doses of study medication. There was an equivalent and significant reduction from baseline levels in the mean symptom score during administration of theophylline suspension (42%; p ≤ 0.001) and aminophylline solution (57%; p ≤ 0.001). Mean values for FEV1 (1.2 versus 1.3 L), FEV1/FVC (77% versus 79%), and reduction in acute metaproterenol use (24% versus 43%) in children receiving theophylline suspension and aminophylline solution revealed no differences between products. Adverse effects were reported more frequently for the aminophylline solution, possibly caused in part to its taste. Of children stating a taste preference, eight of 10 children chose the Theolan Suspension. The suspension demonstrated a lower peak theophylline blood level at a later time (11.6 μg/ml at 3 1 2 hours), compared to the solution (14.6 μg/ml at 1 1 2 hours; p ≤ 0.01). Indexes of theophylline fluctuation during the dosing interval indicated equivalent or reduced variability for the suspension. Relative bioavailability of theophylline suspension was 89% of that for the solution. Theophylline suspension was demonstrated to be an effective 12-hour theophylline dosage form for children with asthma. Its unique liquid presentation allows complete dosage flexibility in a pleasant-tasting vehicle. Theophylline suspension should prove to be useful in patients who require maintenance theophylline therapy, but who cannot take solid oral dosage forms.

Original languageEnglish (US)
Pages (from-to)281-286
Number of pages6
JournalThe Journal of Allergy and Clinical Immunology
Volume82
Issue number2
DOIs
StatePublished - Jan 1 1988

Fingerprint

Theophylline
Suspensions
Pharmacokinetics
Aminophylline
Dosage Forms
Metaproterenol
Bronchodilator Agents
Cross-Over Studies
Biological Availability
Asthma
Maintenance
Therapeutics

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Guill, M. F., Pruitt, A. W., Altman, R. E., Lawless, T. E., Brown, D. A., DuRant, R. H., & Bottini, P. B. (1988). Clinical and pharmacokinetic evaluation of a sustained-release liquid theophylline preparation. The Journal of Allergy and Clinical Immunology, 82(2), 281-286. https://doi.org/10.1016/0091-6749(88)91012-3

Clinical and pharmacokinetic evaluation of a sustained-release liquid theophylline preparation. / Guill, Margaret Frank; Pruitt, Albert W.; Altman, Roy E.; Lawless, Terri E.; Brown, David A.; DuRant, Robert H.; Bottini, Peter B.

In: The Journal of Allergy and Clinical Immunology, Vol. 82, No. 2, 01.01.1988, p. 281-286.

Research output: Contribution to journalArticle

Guill, MF, Pruitt, AW, Altman, RE, Lawless, TE, Brown, DA, DuRant, RH & Bottini, PB 1988, 'Clinical and pharmacokinetic evaluation of a sustained-release liquid theophylline preparation', The Journal of Allergy and Clinical Immunology, vol. 82, no. 2, pp. 281-286. https://doi.org/10.1016/0091-6749(88)91012-3
Guill, Margaret Frank ; Pruitt, Albert W. ; Altman, Roy E. ; Lawless, Terri E. ; Brown, David A. ; DuRant, Robert H. ; Bottini, Peter B. / Clinical and pharmacokinetic evaluation of a sustained-release liquid theophylline preparation. In: The Journal of Allergy and Clinical Immunology. 1988 ; Vol. 82, No. 2. pp. 281-286.
@article{3333e86193fc443585c86b03c450601d,
title = "Clinical and pharmacokinetic evaluation of a sustained-release liquid theophylline preparation",
abstract = "Theolan Suspension is the first long-acting liquid theophylline dosage form. A crossover study comparing the pharmacokinetic and clinical response to Theolan Suspension (administered every 12 hours) with aminophylline solution (administered every 8 hours) in children younger than 12 years of age is reported. Twenty-seven patients completed the study: 17 children were aged 6 years or younger and five patients were 3 years or younger. All patients were withdrawn from bronchodilator therapy and then were titrated to clinically effective doses of study medication. There was an equivalent and significant reduction from baseline levels in the mean symptom score during administration of theophylline suspension (42{\%}; p ≤ 0.001) and aminophylline solution (57{\%}; p ≤ 0.001). Mean values for FEV1 (1.2 versus 1.3 L), FEV1/FVC (77{\%} versus 79{\%}), and reduction in acute metaproterenol use (24{\%} versus 43{\%}) in children receiving theophylline suspension and aminophylline solution revealed no differences between products. Adverse effects were reported more frequently for the aminophylline solution, possibly caused in part to its taste. Of children stating a taste preference, eight of 10 children chose the Theolan Suspension. The suspension demonstrated a lower peak theophylline blood level at a later time (11.6 μg/ml at 3 1 2 hours), compared to the solution (14.6 μg/ml at 1 1 2 hours; p ≤ 0.01). Indexes of theophylline fluctuation during the dosing interval indicated equivalent or reduced variability for the suspension. Relative bioavailability of theophylline suspension was 89{\%} of that for the solution. Theophylline suspension was demonstrated to be an effective 12-hour theophylline dosage form for children with asthma. Its unique liquid presentation allows complete dosage flexibility in a pleasant-tasting vehicle. Theophylline suspension should prove to be useful in patients who require maintenance theophylline therapy, but who cannot take solid oral dosage forms.",
author = "Guill, {Margaret Frank} and Pruitt, {Albert W.} and Altman, {Roy E.} and Lawless, {Terri E.} and Brown, {David A.} and DuRant, {Robert H.} and Bottini, {Peter B.}",
year = "1988",
month = "1",
day = "1",
doi = "10.1016/0091-6749(88)91012-3",
language = "English (US)",
volume = "82",
pages = "281--286",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Clinical and pharmacokinetic evaluation of a sustained-release liquid theophylline preparation

AU - Guill, Margaret Frank

AU - Pruitt, Albert W.

AU - Altman, Roy E.

AU - Lawless, Terri E.

AU - Brown, David A.

AU - DuRant, Robert H.

AU - Bottini, Peter B.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - Theolan Suspension is the first long-acting liquid theophylline dosage form. A crossover study comparing the pharmacokinetic and clinical response to Theolan Suspension (administered every 12 hours) with aminophylline solution (administered every 8 hours) in children younger than 12 years of age is reported. Twenty-seven patients completed the study: 17 children were aged 6 years or younger and five patients were 3 years or younger. All patients were withdrawn from bronchodilator therapy and then were titrated to clinically effective doses of study medication. There was an equivalent and significant reduction from baseline levels in the mean symptom score during administration of theophylline suspension (42%; p ≤ 0.001) and aminophylline solution (57%; p ≤ 0.001). Mean values for FEV1 (1.2 versus 1.3 L), FEV1/FVC (77% versus 79%), and reduction in acute metaproterenol use (24% versus 43%) in children receiving theophylline suspension and aminophylline solution revealed no differences between products. Adverse effects were reported more frequently for the aminophylline solution, possibly caused in part to its taste. Of children stating a taste preference, eight of 10 children chose the Theolan Suspension. The suspension demonstrated a lower peak theophylline blood level at a later time (11.6 μg/ml at 3 1 2 hours), compared to the solution (14.6 μg/ml at 1 1 2 hours; p ≤ 0.01). Indexes of theophylline fluctuation during the dosing interval indicated equivalent or reduced variability for the suspension. Relative bioavailability of theophylline suspension was 89% of that for the solution. Theophylline suspension was demonstrated to be an effective 12-hour theophylline dosage form for children with asthma. Its unique liquid presentation allows complete dosage flexibility in a pleasant-tasting vehicle. Theophylline suspension should prove to be useful in patients who require maintenance theophylline therapy, but who cannot take solid oral dosage forms.

AB - Theolan Suspension is the first long-acting liquid theophylline dosage form. A crossover study comparing the pharmacokinetic and clinical response to Theolan Suspension (administered every 12 hours) with aminophylline solution (administered every 8 hours) in children younger than 12 years of age is reported. Twenty-seven patients completed the study: 17 children were aged 6 years or younger and five patients were 3 years or younger. All patients were withdrawn from bronchodilator therapy and then were titrated to clinically effective doses of study medication. There was an equivalent and significant reduction from baseline levels in the mean symptom score during administration of theophylline suspension (42%; p ≤ 0.001) and aminophylline solution (57%; p ≤ 0.001). Mean values for FEV1 (1.2 versus 1.3 L), FEV1/FVC (77% versus 79%), and reduction in acute metaproterenol use (24% versus 43%) in children receiving theophylline suspension and aminophylline solution revealed no differences between products. Adverse effects were reported more frequently for the aminophylline solution, possibly caused in part to its taste. Of children stating a taste preference, eight of 10 children chose the Theolan Suspension. The suspension demonstrated a lower peak theophylline blood level at a later time (11.6 μg/ml at 3 1 2 hours), compared to the solution (14.6 μg/ml at 1 1 2 hours; p ≤ 0.01). Indexes of theophylline fluctuation during the dosing interval indicated equivalent or reduced variability for the suspension. Relative bioavailability of theophylline suspension was 89% of that for the solution. Theophylline suspension was demonstrated to be an effective 12-hour theophylline dosage form for children with asthma. Its unique liquid presentation allows complete dosage flexibility in a pleasant-tasting vehicle. Theophylline suspension should prove to be useful in patients who require maintenance theophylline therapy, but who cannot take solid oral dosage forms.

UR - http://www.scopus.com/inward/record.url?scp=0023790262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023790262&partnerID=8YFLogxK

U2 - 10.1016/0091-6749(88)91012-3

DO - 10.1016/0091-6749(88)91012-3

M3 - Article

C2 - 3403868

AN - SCOPUS:0023790262

VL - 82

SP - 281

EP - 286

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 2

ER -